Advertisement

Use of a combination of CEA and tumor budding to identify high-risk patients with stage II colon cancer

Abstract

Background

High-risk patients with stage II colon cancer may benefit from adjuvant chemotherapy, but identifying this patient population can be difficult. We assessed the prognosis value for predicting tumor progression in patients with stage II colon cancer, of a panel of 2 biomarkers for colon cancer: tumor budding and preoperative carcinoembryonic antigen (CEA).

Methods

Consecutive patients (N = 134) with stage II colon cancer who underwent curative surgery from 2000 to 2007 were included. Multivariate analysis was used to evaluate the association of CEA and tumor budding grade with 5-year disease-free survival (DFS). The prognostic accuracy of CEA, tumor budding grade and the combination of both (CEA-budding panel) was determined.

Results

The study found that both CEA and tumor budding grade were associated with 5-year DFS. The prognostic accuracy for disease progression was higher for the CEA-budding panel (82.1%) than either CEA (70.9%) or tumor budding grade (72.4%) alone.

Conclusions

The findings indicate that the combination of CEA levels and tumor budding grade has greater prognostic value for identifying patients with stage II colon cancer who are at high-risk for disease progression, than either marker alone.

Int J Biol Markers 2017; 32(3): e267 - e273

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.5301/jbm.5000255

Authors

Changzheng Du, Weicheng Xue, Fangyuan Dou, Yifan Peng, Yunfeng Yao, Jun Zhao, Jin Gu

Article History

Disclosures

Financial support: This work was supported by Capital Heath Development Funding “Beijing Municipal Commission of Health and Family Planning” (grant no. SHOUFA-2011-2015-03).
Conflict of interest: None of the authors has any financial interest related to this study to disclose.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  • Department of Gastroenterology Center, Peking University Cancer Hospital, Beijing - PR China
  • Department of Pathology, Peking University Cancer Hospital, Beijing - PR China
  • Changzheng Du and Weicheng Xue contributed equally to this work.

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.